Lido Advisors
ALXO icon

Lido Advisors’s ALX Oncology ALXO Stock Holding History

Lido Advisors’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$26.5K Hold
13,220
– – ﹤0.01% 1922
2025
Q4 		$24.2K Hold
13,220
– – ﹤0.01% 1911
2025
Q3 		$24.2K Hold
13,220
– – ﹤0.01% 1814
2025
Q2 		$5.49K Hold
13,220
– – ﹤0.01% 1651
2025
Q1 		$8.24K Hold
13,220
– – ﹤0.01% 1501
2024
Q4 		$22.1K Buy
+13,220
New +$20.3K ﹤0.01% 1484

Other funds holding ALXO

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

Lido Advisors's ALXO Position: Q1 2026 in Review

Lido Advisors held its ALX Oncology (ALXO) position steady in Q1 2026 at 13,220 shares worth $26.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1922.

Lido Advisors first reported a position in ALXO in Q4 2024 and has held it in 6 quarters since. 69 funds tracked by Wall St. Rank hold ALXO as of Q1 2026.

  • Lido Advisors held 13,220 shares of ALX Oncology worth $26.5K as of Q1 2026.
  • Lido Advisors left its ALX Oncology share count unchanged in Q1 2026.
  • ALX Oncology made up ﹤0.01% of Lido Advisors's portfolio in Q1 2026, its #1922 holding.
  • Lido Advisors first reported a position in ALX Oncology in Q4 2024 and has held it in 6 quarters since.
  • 69 funds tracked by Wall St. Rank held ALX Oncology as of Q1 2026.

Based on Lido Advisors's 13F filing for Q1 2026, filed 13 May 2026.